“Age Reversal Breakthroughs, FDA Approval, and Living Forever” — David Sinclair AMA

Episode summary

A short AMA format episode with Diamandis and David Sinclair fielding audience questions, moderated by producer Nick. Key topics: why longevity therapies are slow to market (drug development costs $400-500M with high failure rates, FDA safety-first mandate), current available interventions (metformin, rapamycin), Sinclair’s Metro Biotech NAD booster in Phase 2 trials (2-3 years from market), epigenetic reprogramming of the eye to cure blindness moving from mice to non-human primates, and the upcoming $101M Age Reversal XPRIZE (co-chaired by Sinclair and George Church). The prize targets: a therapeutic lasting less than 1 year that reverses biological age by 20+ years, measured across cognition, muscle, skin, and immune function. Sinclair estimates 150 years achievable in current lifespans but not immortality. Diamandis advocates for “accredited patient” programs to broaden access to experimental treatments. Brief discussion of cryonics. Sinclair notes the US alone would gain $86 trillion in economic value from adding one healthy year to average lifespan.

Key arguments / segments

[00:02:00] Why longevity therapies are slow: $400-500M per drug, FDA safety mandate, most doctors unwilling to prescribe to healthy patients
[00:03:00] Metro Biotech NAD booster in Phase 2, epigenetic eye reprogramming moving to primates
[00:04:00] FDA as safety-first org: lives lost from approved bad drugs valued more than lives lost from non-approval
[00:07:00] FDA receptive to aging-as-treatable-condition; bureaucratic rules limit speed
[00:09:00] “Accredited patient” concept for experimental access
[00:14:00] “Kicking the can” — 150 years achievable, not immortality
[00:19:00] $101M Age Reversal XPRIZE: reverse biological age by 20+ years in under 1 year
[00:22:00] $86 trillion economic impact of adding one healthy year (US alone)

Bias / commercial flags

Sinclair has commercial interests in Metro Biotech (NAD booster company spun out of his lab)
Diamandis co-chairs the XPRIZE being discussed
Sinclair discloses taking metformin and rapamycin personally

RDCO relevance

Low direct relevance. Longevity science is outside RDCO’s core focus. The XPRIZE incentive-prize model and FDA regulatory dynamics are useful background knowledge but not actionable. No AI signal beyond brief mention of future AI/robotics accelerating longevity timelines.